Tenet Healthcare Corporation (NYSE:THC) Receives Consensus Rating of "Moderate Buy" from Analysts

Key Points

• Analysts give Tenet a consensus rating of "Moderate Buy" from 22 firms with an average 1-year price target of $250.56, and multiple brokers have recently raised targets (UBS to $288, Morgan Stanley $260, Jefferies $265).
• Tenet beat quarterly expectations with $4.70 EPS vs. $4.08 est. and $5.53B revenue (up 8.9% YoY), and set FY2026 EPS guidance of $16.19–18.47.
• Insiders have been net sellers (46,517 shares sold in the last 90 days, ~$10.94M), leaving insiders with 0.81% ownership while institutional investors hold 95.44% of the stock.

Tenet Healthcare Corporation (NYSE:THC - Get Free Report) has been given a consensus recommendation of "Moderate Buy" by the twenty-two ratings firms that are covering the stock, MarketBeat.com reports. Three research analysts have rated the stock with a hold rating, eighteen have assigned a buy rating and one has issued a strong buy rating on the company. The average 1-year price objective among brokers that have issued ratings on the stock in the last year is $250.5556.

THC has been the topic of a number of research reports. UBS Group upped their price target on shares of Tenet Healthcare from $260.00 to $288.00 and gave the company a "buy" rating in a research note on Thursday, February 12th. Jefferies Financial Group raised their target price on shares of Tenet Healthcare from $250.00 to $265.00 and gave the stock a "buy" rating in a report on Thursday, February 12th. KeyCorp raised their target price on shares of Tenet Healthcare from $225.00 to $250.00 and gave the stock an "overweight" rating in a report on Thursday, February 12th. Morgan Stanley reaffirmed an "overweight" rating and set a $260.00 target price on shares of Tenet Healthcare in a report on Thursday, February 12th. Finally, Mizuho raised their target price on shares of Tenet Healthcare from $235.00 to $265.00 and gave the stock an "outperform" rating in a report on Thursday, March 12th.

Tenet Healthcare Stock Down 1.2%

Shares of THC opened at $192.86 on Tuesday. Tenet Healthcare has a 52 week low of $109.82 and a 52 week high of $247.21. The firm has a market cap of $16.77 billion, a P/E ratio of 12.45, a price-to-earnings-growth ratio of 0.94 and a beta of 1.49. The firm's 50-day simple moving average is $214.25 and its 200 day simple moving average is $205.41. The company has a debt-to-equity ratio of 2.18, a quick ratio of 1.68 and a current ratio of 1.76.

Tenet Healthcare (NYSE:THC - Get Free Report) last announced its quarterly earnings results on Wednesday, February 11th. The company reported $4.70 EPS for the quarter, beating analysts' consensus estimates of $4.08 by $0.62. Tenet Healthcare had a net margin of 6.60% and a return on equity of 26.33%. The business had revenue of $5.53 billion for the quarter, compared to analyst estimates of $5.47 billion. During the same quarter in the prior year, the business earned $3.44 EPS. Tenet Healthcare's quarterly revenue was up 8.9% on a year-over-year basis. Tenet Healthcare has set its FY 2026 guidance at 16.190-18.470 EPS. On average, analysts forecast that Tenet Healthcare will post 12.24 earnings per share for the current year.

Insider Transactions at Tenet Healthcare

In related news, EVP Paola M. Arbour sold 6,500 shares of the stock in a transaction that occurred on Wednesday, March 11th. The shares were sold at an average price of $238.43, for a total transaction of $1,549,795.00. Following the sale, the executive vice president owned 29,291 shares in the company, valued at approximately $6,983,853.13. This trade represents a 18.16% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. Also, EVP Thomas W. Arnst sold 24,000 shares of the stock in a transaction that occurred on Monday, March 2nd. The stock was sold at an average price of $234.04, for a total transaction of $5,616,960.00. Following the sale, the executive vice president owned 8,012 shares in the company, valued at $1,875,128.48. This represents a 74.97% decrease in their position. The disclosure for this sale is available in the SEC filing. Over the last ninety days, insiders have sold 46,517 shares of company stock valued at $10,943,111. 0.81% of the stock is currently owned by company insiders.

Institutional Trading of Tenet Healthcare

Several large investors have recently made changes to their positions in the company. Triumph Capital Management bought a new position in Tenet Healthcare in the 3rd quarter valued at approximately $25,000. Activest Wealth Management bought a new position in Tenet Healthcare in the 4th quarter valued at approximately $26,000. Elyxium Wealth LLC bought a new position in Tenet Healthcare in the 4th quarter valued at approximately $29,000. William B. Walkup & Associates Inc. bought a new position in Tenet Healthcare in the 3rd quarter valued at approximately $32,000. Finally, Canada Pension Plan Investment Board bought a new position in Tenet Healthcare in the 2nd quarter valued at approximately $35,000. Institutional investors and hedge funds own 95.44% of the company's stock.

About Tenet Healthcare

Tenet Healthcare Corporation NYSE: THC is a diversified American healthcare services company that owns and operates acute care hospitals and a broad range of outpatient facilities. Its portfolio includes general acute-care hospitals, specialty hospitals, ambulatory surgery centers, urgent care and diagnostic imaging centers, and other ancillary service locations. Tenet's operations are oriented around delivering inpatient and outpatient clinical care across multiple medical specialties, with an emphasis on surgical services, emergency care, and advanced diagnostics.

In addition to facility-based care, Tenet provides integrated services designed to support clinical operations and improve patient access and care coordination.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.